Off-the-shelf natural killer cells to sweep up residual disease
Donor immune cells that need no matching could be given as short courses to clear the few cancer cells left after surgery, when the target is smallest.
Allogeneic natural killer and CAR-NK products have been limited by short persistence and modest activity against bulky solid tumours, but persistence matters far less when the target is a handful of disseminated cells. Combined with a cytokine support agent, repeat dosing in the molecular residual disease window is a rational use of a product class that has struggled in advanced disease.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Pages like this
not linked directly; found by shared links- IdeaQualify one iPSC master cell bank once for many off-the-shelf cell products
Shares Fate Therapeutics, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines.
- InstitutionMasonic Cancer Center, University of Minnesota
Shares Fate Therapeutics, CAR-NK & CAR-macrophage, Allogeneic (off-the-shelf) cell therapy.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
- IdeaMetastasis prevention as a formal indication with its own trials and regulatory pathway
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC), Colorectal cancer.
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
- IdeaPersonalised vaccines given only when the blood test turns positive
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Manufacturing cost and time for living and radioactive medicines, MRD / molecular residual disease testing.
- IdeaBlock the recycling that keeps dormant cells alive
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
- IdeaPlan the second CAR-T target before the first one is lost
Shares Allogeneic (off-the-shelf) cell therapy, Minimal / molecular residual disease (MRD), Manufacturing cost and time for living and radioactive medicines, MRD / molecular residual disease testing.